BACKGROUND: Obesity is associated with systemic and intestine-specific inflammation and alterations in gut microbiota, which in turn impact mucosal immunity. Nonetheless, a specific role of obesity and its interaction with genetics in the progression of Crohn's disease (CD) is unclear. METHODS: We conducted a cross-sectional study of patients with CD enrolled in Prospective Registry in Inflammatory Bowel Disease Study at Massachusetts General Hospital (PRISM). Information on diagnosis of CD and its complications were collected and confirmed through review of medical records. A genetic risk score was calculated using previously reported single-nucleotide polymorphisms-associated genome-wide with CD susceptibility. We used logistic regression to estimate the effect of body mass index (BMI) and its interaction with genetic risk on risk of CD complications. RESULTS: Among 846 patients with CD, 350 required surgery, 242 with penetrating disease, 182 with stricturing disease, and 226 with perianal disease. There were no associations between obesity (BMI ≥ 30 kg/m2) and risk of perianal disease, stricturing disease, or surgery. Compared with normal-weight individuals with BMI < 25 kg/m2, obesity was associated with lower risk of penetrating disease (odds ratio [OR = 0.56; 95% confidence interval [CI], 0.31-0.99). This association persists among a subgroup of participants with available BMI before development of penetrating disease (OR = 0.40; 95% CI, 0.16-0.88). There were no interactions between BMI and genetic risk score on risk of CD complications (all P interaction > 0.28). CONCLUSIONS: Our data suggest that obesity does not negatively impact long-term progression of CD, even after accounting for genetic predisposition.
BACKGROUND:Obesity is associated with systemic and intestine-specific inflammation and alterations in gut microbiota, which in turn impact mucosal immunity. Nonetheless, a specific role of obesity and its interaction with genetics in the progression of Crohn's disease (CD) is unclear. METHODS: We conducted a cross-sectional study of patients with CD enrolled in Prospective Registry in Inflammatory Bowel Disease Study at Massachusetts General Hospital (PRISM). Information on diagnosis of CD and its complications were collected and confirmed through review of medical records. A genetic risk score was calculated using previously reported single-nucleotide polymorphisms-associated genome-wide with CD susceptibility. We used logistic regression to estimate the effect of body mass index (BMI) and its interaction with genetic risk on risk of CD complications. RESULTS: Among 846 patients with CD, 350 required surgery, 242 with penetrating disease, 182 with stricturing disease, and 226 with perianal disease. There were no associations between obesity (BMI ≥ 30 kg/m2) and risk of perianal disease, stricturing disease, or surgery. Compared with normal-weight individuals with BMI < 25 kg/m2, obesity was associated with lower risk of penetrating disease (odds ratio [OR = 0.56; 95% confidence interval [CI], 0.31-0.99). This association persists among a subgroup of participants with available BMI before development of penetrating disease (OR = 0.40; 95% CI, 0.16-0.88). There were no interactions between BMI and genetic risk score on risk of CD complications (all P interaction > 0.28). CONCLUSIONS: Our data suggest that obesity does not negatively impact long-term progression of CD, even after accounting for genetic predisposition.
Authors: Mark S Silverberg; Jack Satsangi; Tariq Ahmad; Ian D R Arnott; Charles N Bernstein; Steven R Brant; Renzo Caprilli; Jean-Frédéric Colombel; Christoph Gasche; Karel Geboes; Derek P Jewell; Amir Karban; Edward V Loftus; A Salvador Peña; Robert H Riddell; David B Sachar; Stefan Schreiber; A Hillary Steinhart; Stephan R Targan; Severine Vermeire; B F Warren Journal: Can J Gastroenterol Date: 2005-09 Impact factor: 3.522
Authors: K Yamamoto; T Kiyohara; Y Murayama; S Kihara; Y Okamoto; T Funahashi; T Ito; R Nezu; S Tsutsui; J-I Miyagawa; S Tamura; Y Matsuzawa; I Shimomura; Y Shinomura Journal: Gut Date: 2005-06 Impact factor: 23.059
Authors: Konstantinos Karmiris; Ioannis E Koutroubakis; Costas Xidakis; Maria Polychronaki; Theodora Voudouri; Elias A Kouroumalis Journal: Inflamm Bowel Dis Date: 2006-02 Impact factor: 5.325
Authors: P Desreumaux; O Ernst; K Geboes; L Gambiez; D Berrebi; H Müller-Alouf; S Hafraoui; D Emilie; N Ectors; M Peuchmaur; A Cortot; M Capron; J Auwerx; J F Colombel Journal: Gastroenterology Date: 1999-07 Impact factor: 22.682
Authors: Angela Ehling; Andreas Schäffler; Hans Herfarth; Ingo H Tarner; Sven Anders; Oliver Distler; Gisela Paul; Jörg Distler; Steffen Gay; Jürgen Schölmerich; Elena Neumann; Ulf Müller-Ladner Journal: J Immunol Date: 2006-04-01 Impact factor: 5.422
Authors: Jerry R Greenfield; Katherine Samaras; Arthur B Jenkins; Paul J Kelly; Tim D Spector; J Ruth Gallimore; Mark B Pepys; Lesley V Campbell Journal: Circulation Date: 2004-06-07 Impact factor: 29.690
Authors: Kimberley W J Van Der Sloot; Amit D Joshi; Danielle R Bellavance; Katherine K Gilpin; Kathleen O Stewart; Paul Lochhead; John J Garber; Cosmas Giallourakis; Vijay Yajnik; Ashwin N Ananthakrishnan; Behrooz Z Alizadeh; Ramnik J Xavier; Hamed Khalili Journal: Inflamm Bowel Dis Date: 2017-01 Impact factor: 5.325
Authors: S Kurnool; N H Nguyen; J Proudfoot; P S Dulai; B S Boland; N Vande Casteele; E Evans; E L Grunvald; A Zarrinpar; W J Sandborn; S Singh Journal: Aliment Pharmacol Ther Date: 2018-04-17 Impact factor: 8.171
Authors: Tracey G Simon; Kimberley W J Van Der Sloot; Samantha B Chin; Amit D Joshi; Paul Lochhead; Ashwin N Ananthakrishnan; Ramnik Xavier; Raymond T Chung; Hamed Khalili Journal: Inflamm Bowel Dis Date: 2018-09-15 Impact factor: 5.325
Authors: Po-Hong Liu; Kristin E Burke; Ashwin N Ananthakrishnan; Paul Lochhead; Ola Olen; Jonas F Ludvigsson; James M Richter; Andrew T Chan; Hamed Khalili Journal: Clin Gastroenterol Hepatol Date: 2018-12-06 Impact factor: 11.382